Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
July 19 2018 - 4:00PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company that designs and develops innovative human
enzyme therapeutics for patients with rare genetic diseases and
cancer, today announced the appointment of Anthony G. Quinn, M.B
Ch.B, Ph.D. as the Company’s President and Chief Executive Officer,
effective immediately. Dr. Quinn has been a member of the Company’s
Board of Directors since 2016 and had served as interim CEO since
July 2017.
“Aeglea has made great progress over the last 12 months with
compelling data from the Company’s lead program pegzilarginase
under Anthony’s leadership,” said Armen Shanafelt, Ph.D., Chairman
of Aeglea’s Board of Directors. “The Board is looking forward to
continue working with him as we progress through the next phase of
Aeglea’s evolution. In addition to his technical expertise, Anthony
has shown himself to be an extremely talented executive who focuses
on patients and on delivering shareholder value. As a Board, we are
excited by both the potential of Aeglea’s pipeline and the
clinically relevant treatment effects seen with pegzilarginase in
patients with Arginase 1 Deficiency.”
“I am honored to have the opportunity to lead Aeglea at this
stage in the Company’s development and thrilled to be able to shape
the next stage of our journey with the Aeglea team as we advance
therapies with the potential to improve the lives of patients with
devastating diseases,” said Dr. Quinn. “The Company occupies a
unique and exciting area in the biotechnology industry with its
focus on discovering novel human enzyme-based therapeutics for
patients with rare genetic diseases and cancer. I believe we are
now well positioned for future growth with our pipeline programs
and our expanded in-house drug-hunting capabilities.”
Prior to joining Aeglea, Dr. Quinn served as executive vice
president, head of research and development, and chief medical
officer at Synageva Biopharma Corp. until the company’s acquisition
by Alexion Pharmaceuticals in 2015. Dr. Quinn previously served as
worldwide head of clinical research and exploratory development for
inflammatory diseases at Roche. He also was a professor of
dermatology at Barts and The London School of Medicine. Dr. Quinn
received his Bachelor of Medical Science and his M.B Ch.B from the
University of Dundee, and his Ph.D. from the University of
Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship
at the University of California San Francisco and is a fellow of
the Royal College of Physicians London.
About Aeglea BioTherapeutics Aeglea is a
clinical-stage biotechnology company that designs and develops
innovative human enzyme therapeutics for patients with rare genetic
diseases and cancer. Aeglea is developing pegzilarginase, its lead
investigational therapy, for the treatment of Arginase 1
Deficiency, as monotherapy in arginine-dependent cancers and in
combination with an immune checkpoint inhibitor for small cell lung
cancer. In addition, Aeglea has an active research pipeline of
other human enzyme-based approaches in both therapeutic areas. For
more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements This
press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, statements we
make regarding our cash forecasts, the timing and success of our
clinical trials and related data, the timing of announcements and
updates relating to our clinical trials and related data, our
ability to enroll patients into our clinical trials, success in our
collaborations and the potential therapeutic benefits and economic
value of our lead product candidate or other product candidates.
Further information on potential risk factors that could affect our
business and its financial results are detailed in our most recent
Quarterly Report on Form 10-Q for the quarter ended March 31,
2018 filed with the Securities and Exchange Commission (SEC), and
other reports as filed with the SEC. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Investor Contact: Charles N. York II Chief
Financial Officer Aeglea BioTherapeutics
investors@aegleabio.com
Media Contact: David Calusdian Sharon Merrill
Associates AGLE@investorrelations.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Sep 2023 to Sep 2024